Temporal Trends and Hospital Variation in Mineralocorticoid Receptor Antagonist Use in Veterans Discharged With Heart Failure

被引:14
作者
Dev, Sandesh [1 ]
Lacy, Mary E. [2 ,3 ]
Masoudi, Frederick A. [4 ]
Wu, Wen-Chih [2 ,3 ]
机构
[1] Phoenix VA Med Ctr, Phoenix, AZ USA
[2] Brown Univ, Providence, RI 02912 USA
[3] Providence VA Med Ctr, Providence, RI USA
[4] Univ Colorado Anschutz Med Campus, Aurora, CO USA
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2015年 / 4卷 / 12期
关键词
appropriateness criteria; quality of care; spironolactone; variation; MYOCARDIAL-INFARCTION; ADMINISTRATIVE DATA; LEVEL VARIATION; MORTALITY; ASSOCIATION; SPIRONOLACTONE; HYPERKALEMIA; DYSFUNCTION; THERAPIES; INSIGHTS;
D O I
10.1161/JAHA.115.002268
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background-Despite concerns about mineralocorticoid receptor antagonist therapies (MRAs) underuse and misuse in patients with heart failure, temporal and institutional variations of MRA prescription have not been reported. Methods and Results-We studied a national sample of veterans hospitalized for heart failure between 2003 and 2009 and left ventricular ejection fraction <40%. We identified ideal and non-ideal candidates for MRA therapy based on American College of Cardiology/American Heart Association guidelines. We measured temporal trends and hospital variation of MRA prescriptions within 90 days after discharge. We determined the median odds ratio (MOR), a measure of the relative odds of an MRA prescription for 2 individuals with similar characteristics discharged at 2 randomly selected hospitals. From 37 126 patients (n=131 hospitals), 9355 were ideal-MRA candidates, and 4056 were non-ideal candidates. Among ideal candidates, 36% received an MRA, but there was a decline in use (41% in 2003 to 31% in 2009, P<0.001). Of non-ideal candidates, 27% received an MRA with a decline in use (34% in 2003 to 22% in 2009, P<0.001). Hospital MRA prescription ranged from 0% to 71% for ideal candidates and 0% to 100% for non-ideal candidates. The median odds ratios of MRA prescription for ideal and non-ideal candidates were 1.44 and 1.36, respectively; a median odds ratio >1.2 indicates significant practice-level variation. Conclusions-There was decreasing MRA use between 2003 and 2009 with wide institutional variation in MRA prescription, which suggests opportunities for improvement to stimulate MRA use in ideal candidates while further reducing use in those with contraindications.
引用
收藏
页数:12
相关论文
共 22 条
[1]
Use of Aldosterone Antagonists in Heart Failure [J].
Albert, Nancy M. ;
Yancy, Clyde W. ;
Liang, Li ;
Zhao, Xin ;
Hernandez, Adrian F. ;
Peterson, Eric D. ;
Cannon, Christopher P. ;
Fonarow, Gregg C. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (15) :1658-1665
[2]
Association of systolic blood pressure with mortality in patients with heart failure with reduced ejection fraction: A complex relationship [J].
Ather, Sameer ;
Chan, Wenyaw ;
Chillar, Annirudha ;
Aguilar, David ;
Pritchett, Allison M. ;
Ramasubbu, Kumudha ;
Wehrens, Xander H. T. ;
Deswal, Anita ;
Bozkurt, Biykem .
AMERICAN HEART JOURNAL, 2011, 161 (03) :567-573
[3]
Utilization Pattern of Mineralocorticoid Receptor Antagonists in Contemporary Patients Hospitalized With Acute Decompensated Heart Failure: A Single-Center Experience [J].
Chamsi-Pasha, Mohammed A. ;
Dupont, Matthias ;
Al Jaroudi, Wael A. ;
Tang, W. H. Wilson .
JOURNAL OF CARDIAC FAILURE, 2014, 20 (04) :229-235
[4]
Practice-Level Variation in Warfarin Use Among Outpatients With Atrial Fibrillation (from the NCDR PINNACLE Program) [J].
Chan, Paul S. ;
Maddox, Thomas M. ;
Tang, Fengming ;
Spinler, Sarah ;
Spertus, John A. .
AMERICAN JOURNAL OF CARDIOLOGY, 2011, 108 (08) :1136-1140
[5]
Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure [J].
Curtis, Lesley H. ;
Mi, Xiaojuan ;
Qualls, Laura G. ;
Check, Devon K. ;
Hammill, Bradley G. ;
Hammill, Stephen C. ;
Heidenreich, Paul A. ;
Masoudi, Frederick A. ;
Setoguchi, Soko ;
Hernandez, Adrian F. ;
Fonarow, Gregg C. .
AMERICAN HEART JOURNAL, 2013, 165 (06) :979-+
[6]
Comorbidity measures for use with administrative data [J].
Elixhauser, A ;
Steiner, C ;
Harris, DR ;
Coffey, RN .
MEDICAL CARE, 1998, 36 (01) :8-27
[7]
Potential impact of optimal implementation of evidence-based heart failure therapies on mortality [J].
Fonarow, Gregg C. ;
Yancy, Clyde W. ;
Hernandez, Adrian F. ;
Peterson, Eric D. ;
Spertus, John A. ;
Heidenreich, Paul A. .
AMERICAN HEART JOURNAL, 2011, 161 (06) :1024-U244
[8]
Improving Evidence-Based Care for Heart Failure in Outpatient Cardiology Practices Primary Results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) [J].
Fonarow, Gregg C. ;
Albert, Nancy M. ;
Curtis, Anne B. ;
Stough, Wendy Gattis ;
Gheorghiade, Mihai ;
Heywood, J. Thomas ;
McBride, Mark L. ;
Inge, Patches Johnson ;
Mehra, Mandeep R. ;
O'Connor, Christopher M. ;
Reynolds, Dwight ;
Walsh, Mary Norine ;
Yancy, Clyde W. .
CIRCULATION, 2010, 122 (06) :585-U114
[9]
Renal Function Trajectories and Clinical Outcomes in Acute Heart Failure [J].
Givertz, Michael M. ;
Postmus, Douwe ;
Hillege, Hans L. ;
Mansoor, George A. ;
Massie, Barry M. ;
Davison, Beth A. ;
Ponikowski, Piotr ;
Metra, Marco ;
Teerlink, John R. ;
Cleland, John G. F. ;
Dittrich, Howard C. ;
O'Connor, Christopher M. ;
Cotter, Gad ;
Voors, Adriaan A. .
CIRCULATION-HEART FAILURE, 2014, 7 (01) :59-67
[10]
Characteristics and Outcomes of Patients With Advanced Chronic Systolic Heart Failure Receiving Care at the Veterans Affairs Versus Other Hospitals Insights From the Beta-blocker Evaluation of Survival Trial (BEST) [J].
Jones, Linda G. ;
Sin, Mo-Kyung ;
Hage, Fadi G. ;
Kheirbek, Raya E. ;
Morgan, Charity J. ;
Zile, Michael R. ;
Wu, Wen-Chih ;
Deedwania, Prakash ;
Fonarow, Gregg C. ;
Aronow, Wilbert S. ;
Prabhu, Sumanth D. ;
Fletcher, Ross D. ;
Ahmed, Ali ;
Allman, Richard M. .
CIRCULATION-HEART FAILURE, 2015, 8 (01) :17-24